What role does piroxicam play in the management of this disease?
Piroxicam (feldene) is a non-steroidal anti-inflammatory agent, has been shown to reduce the severity of clinical signs associated with urinary bladder and urethral cancer. In some patients, long-term use may result in tumor regression, most likely due to the angiogenesis inhibiting (prevention of blood vessel growth) effects of this drug. The alleviation of dysuria (painful urination) in affected patients makes this therapeutic option very attractive for clients seeking to obtain additional quality time with their pet. This palliative measure can therefore be a viable option for non-resectable urinary tract neoplasia.
